RxDoctor Payments Data

Teresa Green

Physician Assistant · Owasso, OKNPI 1295700425

Payments from drug & device makers

$3,324in general payments, 2019–2025

Across 109 payments — averaging $30.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$481
  • Teva Pharmaceuticals USA, Inc.$475
  • Vanda Pharmaceuticals Inc.$447
  • Johnson & Johnson$411
  • Alkermes, Inc.$285
  • Otsuka America Pharmaceutical, Inc.$237
  • plus $987 from 9 others

What the payments were for

  • Food & beverage$3,10894%
  • Education$2166%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,324 in reported general payments places this provider in the 85th percentile of 1,491 physician assistant providers in Oklahoma.

See all physician assistant providers in Oklahoma

Medicare billing

Part B allowed, 2024
$26,895
Medicare patients
90
Services billed
557

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SpravatoEsketamine Hcl28$38,435
VraylarCariprazine Hcl14$22,945
RexultiBrexpiprazole11$17,633
XanaxAlprazolam11$5,841
Quetiapine Fumarate69$4,734
Memantine Hcl28$1,993
Aripiprazole12$1,939
Doxepin Hcl74$1,779
Atomoxetine Hcl11$1,713
Lamotrigine63$1,398
Risperidone53$833
Alprazolam ErAlprazolam20$800
Olanzapine47$562
Buspirone Hcl39$538
Mirtazapine31$528

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonSpravato$411$38,43528 claims
AbbVieVraylar$481$22,94514 claims
Otsuka America Pharmaceutical, Inc.Rexulti$237$17,63311 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,491 physician assistant providers in Oklahoma.

Other physician assistant in Owasso

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →